Licensure of a New Hexavalent Vaccine for Use in Infants Licensure of a New Hexavalent Vaccine for Use in Infants

A new hexavalent vaccine for use in children aged 6 weeks through 4 years has been approved by the FDA to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.Morbidity & Mortality Weekly Report
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news